Varenicline for smoking cessation in patients with coronary heart disease

Circulation

Volumn 121, Issue 2, 2010, Pages 188-190

  Ockene, Ira ^a   Salmoirago Blotcher, Elena ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; PLACEBO; VARENICLINE;

BEHAVIOR THERAPY; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; SLEEP DISORDER; SMOKING CESSATION; TOBACCO DEPENDENCE; VOMITING;

BENZAZEPINES; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DRUG TOXICITY; HUMANS; QUINOXALINES; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 74949089254     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.915546     Document Type: Editorial

References (21)

1. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2007. MMWR Morb Mortal Wkly Rep. 2008; 57: 1221-1226.
2. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ. 1994; 309:901-911.
3. Reid DD, McCartney P, Hamilton PJS, Rose G, Jarrett RJ, Keen H. Smoking and other risk factors for coronary heart disease in British civil servants. Lancet. 1976;308:979-984.
4. Yusuf S, Hawken S, Ǒ unpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
5. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86-97.
6. Ockene JK, Kuller LH, Svendsen KH, Meilahn E. The relationship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Public Health. 1990;80:954-958. (Pubitemid 20239414)
7. Barth J, Critchley J, Bengel J. Efficacy of psychosocial interventions for smoking cessation in patients with coronary heart disease: a systematic review and meta-analysis. Ann Behav Med. 2006;32:10-20.
8. Smith PM, Burgess E. Smoking cessation initiated during hospital stay for patients with coronary artery disease: a randomized controlled trial. Can Med Assoc J. 2009;180:1297-1303.
9. Fiore M, Jaén C, Baker T, Benowitz N, Curry S, Dorfman S, Froelicher E, Goldstein M, Healton C, Henderson P, Heyman R, Koh H, Kottke T, Lando H, Mecklenburg R, Mermelstein R, Dolan Mullen P, Tracy Orleans C, Robinson L, Stitzer M, Tommasello A, Villejo L, Wewers M. Treating Tobacco Use And Dependence: Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services; 2008.
10. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, for the Varenicline Phase 3 Study G. Varenicline, an «4/32 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
11. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, for the Varenicline Phase 3 Study G. Efficacy of varenicline, an «4/32 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
12. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, for the Varenicline Phase 3 Study G. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.
13. Klesges RC, Johnson KC, Somes G. Varenicline for smoking cessation: definite promise, but no panacea. JAMA. 2006;296:94-95.
14. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121: 221-229.
15. Kuehn BM. Studies linking smoking-cessation drug with suicide risk spark concerns. JAMA. 2009;301:1007-1008.
16. Ockene JK, Kristeller JL, Goldberg R, Ockene IS, Merriam P, Barrett S, Pekow P, Hosmer D, Gianelly R. Smoking cessation and severity of disease: the Coronary Artery Smoking Intervention Study. Health Psychol. 1992;11:119-126.
17. Mermelstein R, Colby SM, Patten C, Prokhorov A, Brown R, Myers M, Adelman W, Hudmon K, McDonald P. Methodological issues in measuring treatment outcome in adolescent smoking cessation studies. Nicotine Tob Res. 2002;4:395-403.
18. Velicer WF, Prochaska JO, Rossi JS, Snow MG. Assessing outcome in smoking cessation studies. Psychol Bull. 1992;111:23-41.
19. Florescu A, Ferrence R, Einarson T, Selby P, Soldin O, Koren G. Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther Drug Monit. 2009;31:14-30.
20. Velicer WF, Prochaska JO. A comparison of four self-report smoking cessation outcome measures. Addict Behav. 2004;29:51-60.
21. Bolin K, Wilson K, Benhaddi H, Nigris Ed, Marbaix S, Mork A-C, Aubin H-J. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation: results from four European countries. Eur J Public Health. 2009;19:650-654.